X0508 4/A 2025-03-06-05:00 2025-04-17-05:00 false 0000924515 GUIDED THERAPEUTICS INC GTHP 0001348439 Imhoff John E 5853 PEACHTREE CORNERS EAST SUITE B PEACHTREE CORNERS GA 30092 true false true false false Preferred Series D Stock 2025-03-06-05:00 4 J false 300 D 0 D Common Stock 2025-03-06-05:00 4 J false 900000 A 9662756 D Preferred Series C2 Stock 2025-03-06-05:00 4 J true 2400.75 D 0 D Common Stock 2025-03-06-05:00 4 J true 4801500 0.50 A 14464256 D Preferred Series C Stock 2025-03-07-05:00 4 P false 286 A 286 D Preferred Series C Stock 2025-03-11-05:00 4 J false 286 D 0 D Common Stock 2025-03-11-05:00 4 J true 2258690 0.1266 A 16722946 D Preferred Series E Stock 2025-03-13-05:00 4 P false 150 A 400 D Common Stock 2025-03-18-05:00 4 P false 1000000 0.10 A 17722946 D Common Stock 2025-03-18-05:00 4 P false 263069 0.10 A 17986015 D Common Stock 2025-04-10-05:00 4 J false 6365 A 17992380 D Warrants 0.13 2025-03-18-05:00 4 P false 1000000 A 2025-03-18-05:00 2029-03-17-05:00 Common Stock 1000000 1000000 D Warrants 0.13 2025-03-18-05:00 4 P false 263069 A 2025-03-18-05:00 2029-03-17-05:00 Common Stock 263069 1263069 D On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price. On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares. On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares. On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000. In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above. These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943. These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943. /s/ John E. Imhoff 2025-05-23-05:00